Poseida Therapeutics price target raised by $5 at H.C. Wainwright, here’s why

H.C. Wainwright raised the firm’s price target on Poseida Therapeutics to $20 from $15 and keeps a Buy rating on the shares saying the company presented additional positive clinical data from its P-BCMA-ALLO1 program. The analyst says the company “made a splash at ASH.”